Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Status:
Not yet recruiting
Trial end date:
2028-11-20
Target enrollment:
Participant gender:
Summary
This phase II trial test whether combination chemotherapy works to improve blood test results
in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib,
daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. This trial may help determine if patients who have a small amount of
cancer left after the initial treatment, called minimal residual disease, will benefit from
the drug combination.